AudioScholar Dermatology Weekly (India)

Welcome to This Week in Dermatology. This week we are covering five notable papers spanning therapeutic advances and laboratory monitoring in alopecia areata, demographic variations in contact allergen sensitivities, multidimensional success metrics in hidradenitis suppurativa, and a critical update to the global naming system for biological therapies. Let's dive in.

This week's papers:

1. Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study — Journal of the American Academy of Dermatology 2026
2. The Association of Race and Ethnicity with Patch Test Results: North American Contact Dermatitis Group Data, 2007-2020 — Journal of the American Academy of Dermatology 2026
3. Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study — Journal of the American Academy of Dermatology 2026
4. Measuring success in HS treatment from the physician's and the patient's perspective — Journal of the European Academy of Dermatology and Venereology 2026
5. Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice — Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in.

This week's papers:

1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. — Nature medicine 2026
2. Clinical and Dermoscopic Triage of head and neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions. — Journal of the American Academy of Dermatology 2026
3. Comparative effects of interventions for rosacea across phenotype-relevant outcomes: a systematic review and network meta-analysis. — Journal of the American Academy of Dermatology 2026
4. Insulin Resistance is Not a Predictor of Response to Low-Dose Oral Metformin Therapy in Patients with CCCA: A Retrospective Review. — Journal of the American Academy of Dermatology 2026
5. Magnified ultraviolet-induced fluorescence dermatoscopy for assessing mite viability in scabies. — Journal of the American Academy of Dermatology 2026
6. Initial Psychometric Validation of the Caregiver Atopic Dermatitis Control Tool. — Clinical and experimental dermatology 2026
7. High Level of Uncertainty in Assigning Causative Medications in Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Cohort Analysis. — Journal of the American Academy of Dermatology 2026
8. A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations. — Pediatric dermatology 2026
9. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome. — The British journal of dermatology 2026
10. Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution. — Clinical and experimental dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic manifestations and novel therapeutics in psoriasis, real-world outcomes in hair restoration, and emerging safety and diagnostic data in inflammatory dermatoses. Let's dive in.

This week's papers:

1. Efficacy and safety of inhibitory magnetic stimulation in the treatment of refractory erythema of rosacea: a prospective, randomized, controlled clinical trial. — Journal of the American Academy of Dermatology 2026
2. Long-term Real-world Outcomes and Tolerability of Baricitinib in Alopecia Areata, Totalis, and Universalis: A Retrospective Single-center Cohort of 330 Patients with Trichoscopy Monitoring. — Journal of the American Academy of Dermatology 2026
3. Increased Efficacy of Daytime Low-dose Oral Minoxidil Dosing for Androgenetic Alopecia: A Retrospective Study. — The British journal of dermatology 2026
4. Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study. — Journal of the European Academy of Dermatology and Venereology 2026
5. Malignant transformation in mucosal lichen planus: A 10-year, single-center, descriptive cohort analysis. — Journal of the American Academy of Dermatology 2026
6. Pemphigoid was not associated with increased risk of solid organ, hematologic, or nonmelanoma skin malignancies in a nationally representative matched cohort. — Clinical and experimental dermatology 2026
7. Relapse prediction in rituximab-treated pemphigus patients: A prognostic model. — Journal of the European Academy of Dermatology and Venereology 2026
8. Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series. — Journal of the European Academy of Dermatology and Venereology 2026
9. Missed melanoma following skin lesion triage by an autonomous artificial intelligence system in a community setting. — Clinical and experimental dermatology 2026
10. Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma. — Clinical and experimental dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we are covering ten notable papers spanning advanced management strategies for skin cancer, novel therapeutic insights in atopic dermatitis, and optimizing procedural and wound care outcomes. Let us dive in.

This week's papers:

1. Compression therapies for venous leg ulcers: The VENous Ulcer Study 6 (VenUS 6), an open, multicentre, randomised clinical trial. — PLoS medicine 2026
2. Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison. — Journal of the American Academy of Dermatology 2026
3. Recurrence of Basal Cell Carcinoma across Different Treatment Modalities: A Nationwide Study with 8 Years of Follow-up and Modelled Prediction. — Acta dermato-venereologica 2026
4. Acneiform Eruption with Deucravacitinib: Systematic Review and Meta-Analysis. — Clinical and experimental dermatology 2026
5. Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study. — Clinical and experimental dermatology 2026
6. Clinical Predictors and a Novel Diagnostic Nomogram for Non-Bullous Pemphigoid: A 10-year Large-Scale Retrospective Case-Control Study. — Journal of the American Academy of Dermatology 2026
7. Resource Use and Cost Comparison of Mohs Micrographic Surgery vs Traditional Surgery for High-risk Facial Basal Cell Carcinoma. — Acta dermato-venereologica 2026
8. Compression Response During Ultrasound Aids Real-Time Differentiation of Pseudocysts and Tunnels in Hidradenitis Suppurativa. — Journal of the American Academy of Dermatology 2026
9. Assessing Skin Cancer Risk in Systemic Sclerosis Patients with Organ Transplantation: A Cohort Study. — Journal of the American Academy of Dermatology 2026
10. Near-Infrared Vascular Mapping to Guide Procedural Management of Superficial Cutaneous Vascular Lesions. — Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we are covering seven notable papers spanning novel oral therapeutics for psoriasis, hair loss interventions, and complex dermatopathological entities. Let's dive in.

This week's papers:

1. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials. — The British journal of dermatology 2026
2. Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study. — Journal of the American Academy of Dermatology 2026
3. Safety of Biologic Therapy in Psoriasis Patients With Malignancy. — Journal of the American Academy of Dermatology 2026
4. Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study. — Journal of the American Academy of Dermatology 2026
5. Microneedling with adipose MSC exosomes versus monotherapy for androgenetic alopecia. — Journal of the European Academy of Dermatology and Venereology : JEADV 2026
6. Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients. — The British journal of dermatology 2026
7. Genomic Predictors of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Insights from an MD Anderson Cohort. — Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 9 notable papers spanning atopic dermatitis prevention and management, the systemic and behavioral burdens of chronic inflammatory skin diseases, and new insights into cutaneous biology and onco-dermatology. Let's dive in.

This week's papers:

1. Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages. — Journal of the European Academy of Dermatology and Venereology 2026
2. Addiction in chronic inflammatory skin diseases: A systematic review of prevalence, impact and screening practices. — Journal of the European Academy of Dermatology and Venereology 2026
3. Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris. — The Journal of Investigative Dermatology 2026
4. The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue. — The Journal of Investigative Dermatology 2026
5. Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled Trial. — The Journal of Investigative Dermatology 2026
6. Randomised Controlled Feasibility Trial of an Intervention to Reduce Infant Bathing. — The British Journal of Dermatology 2026
7. Male genital fixed drug eruption: a systematic review. — Clinical and Experimental Dermatology 2026
8. Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis. — Clinical and Experimental Dermatology 2026
9. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. — Nature Medicine 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering nine notable papers spanning clinical screening strategies, advanced therapeutics for severe autoimmune and inflammatory conditions, and emerging prognostic models in patient care. Let's dive in.

This week's papers:

1. Outcomes of dermatologist-performed skin cancer screening in an academic setting: a retrospective cohort study. — Journal of the American Academy of Dermatology 2026
2. Cobratide injection vs Pregabalin for Moderate-to-Severe Acute Herpes Zoster Neuralgia: A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Multicenter Exploratory Trial. — Journal of the American Academy of Dermatology 2026
3. OX40 pathway inhibition and Kaposi sarcoma: An emerging safety signal in atopic dermatitis. — Journal of the European Academy of Dermatology and Venereology 2026
4. Isotretinoin is not associated with elevated risk of pseudotumor cerebri: A Danish register-based cohort study. — Journal of the American Academy of Dermatology 2026
5. Diagnosis and management of acyclovir-resistant herpes simplex virus for the dermatologist. — Journal of the American Academy of Dermatology 2026
6. Autoimmune Disease in Central Centrifugal Cicatricial Alopecia: A Multi-Institutional Cross-Sectional Study. — Journal of the American Academy of Dermatology 2026
7. Barbed Suture-Assisted High-Tension Cutaneous Closure: Brief Report of 493 Surgical Defects. — Journal of the American Academy of Dermatology 2026
8. Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus. — The Journal of investigative dermatology 2026
9. Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic review. — Journal of the European Academy of Dermatology and Venereology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 7 notable papers spanning the rise and real-world performance of artificial intelligence, new approaches to prognostication in inflammatory disease and skin cancer, and the complex landscape of genodermatoses from molecular mechanisms to patient counseling. Let's dive in.

This week's papers:

1. General-purpose large language models outperform specialized clinical AI tools on medical benchmarks. — Nature medicine 2026
2. An ITGB4 variant modifies the severity of ITGA3-associated interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa (ILNEB). — The Journal of investigative dermatology 2026
3. Expanding histopathological assessment may provide limited prognostic value for metastatic cutaneous squamous cell carcinoma: insights from two nationwide nested case-control studies. — The British journal of dermatology 2026
4. Effectiveness and safety of hematoporphyrin monomethyl ether-mediated photodynamic therapy versus pulsed dye laser for port-wine stain: a retrospective study. — Journal of the American Academy of Dermatology 2026
5. Microdialysis-based metabolomic and proteomic profiling reveals signature variations for disease severity in psoriasis. — The Journal of investigative dermatology 2026
6. Artificial intelligence in dermatology: Clinical promise and environmental impact. — The Journal of investigative dermatology 2026
7. Patient Perspectives, Unmet Needs and Dilemmas in Reproductive Decision-making for Genodermatoses: A Qualitative Interview Study. — Acta dermato-venereologica 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering several notable papers spanning the profound systemic and psychological burden of skin disease, and a critical look at cancer mortality in our high-risk transplant population. Let's dive in.

This week's papers:

1. Atopic dermatitis. — Nature reviews. Disease primers 2026
2. Skin cancer mortality in Australian and New Zealand kidney transplant recipients: A population-based cohort study using linked health data, 1990-2019. — The British journal of dermatology 2026
3. Suicidal ideation in patients with skin conditions: A multicentre European study. — Journal of the European Academy of Dermatology and Venereology : JEADV 2026
4. Epidermal necrolysis sequelae: A cohort study on prevalence and risk factors. — Journal of the European Academy of Dermatology and Venereology : JEADV 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 4 notable papers spanning the systemic burden of severe skin diseases and recent advances in therapeutics. Let's dive in.

This week's papers:

1. Cardiac involvement in severe cutaneous adverse reactions: a Retrospective Observational Cohort Study of DRESS and SJS/TEN at a major Australian tertiary hospital. — Clin Exp Dermatol 2026
2. Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden. — Acta Derm Venereol 2026
3. Long-Term Efficacy and Safety of Oleogel-S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa. — Pediatr Dermatol 2026
4. Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability. — Br J Dermatol 2026

Listen at AudioScholar